Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Clinical trial NCT00743795 · COMPLETED
Trial details
- NCT number
- NCT00743795
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-10-01
- Primary completion
- 2009-07-01
- Enrollment
- 252
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.